Fibrosis Lessens After Metabolic Surgery

NCT06374875 on ClinicalTrials.gov · last registry update 2026-07-31

Recruiting now, toward 120 participants. Due to report 31 May 2029. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 11 July 2024 — 2 years so far. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: The Cleveland Clinic
Sponsor type: Other
Enrollment: 120
Started: 2024-07-11
Primary completion: 2029-05-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Improvement of at least 1 fibrosis stage of the Kleiner fibrosis classification and no worsening of MASH in the repeat liver biopsy.

Conditions studied

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease · Metabolic Dysfunction-Associated Steatohepatitis (MASH) · Liver Fibrosis · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.